We are live on ! Find out more
APOPW

Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW

Delisted

APOPW was delisted on the 3rd of August, 2021.

Back to rankings

2 hedge funds and large institutions have $3K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2019 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

73% less capital invested

Capital invested by funds: $11K → $3K (-$8K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
–
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$5K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$880
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$2K -$880 -2,307 -12%
CH
2
CVI Holdings
Delaware
$1K – – –

APOPW Hedge Fund Activity: Q1 2019 in Review

2 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q1 2019, worth a combined $3K — down 73% from $11K a quarter earlier.

Fund positioning in APOPW was balanced in Q1 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Susquehanna International Group, cutting an estimated $880.

  • 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $3K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q1 2019, down 73% quarter-over-quarter.
  • 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q1 2019 and 0 closed out.
  • The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs seller in Q1 2019 was Susquehanna International Group, an estimated $880 sold.

Based on aggregated 13F filings for Q1 2019.